| Bioactivity | SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, ERK, p38 and JNK intracellular signaling pathways[1]. | ||||||||||||
| Target | BMP | ||||||||||||
| Invitro | SY-LB-35 (0.01-1000 μM; 24 h) stimulates significant increases in cell number and cell viability in the C2C12 myoblast cell line[1].SY-LB-35 (0.01-10 μM; 30 min or 15 min) stimulates Smad phosphorylation and nuclear translocation, activates the PI3K/Akt pathway and direct the cytoplasmic localization of p-Akt, stimulates the phosphorylation and activation of PI3K in the C2C12 cells[1].SY-LB-35 (0.01-10 μM; 24 h) causes the cell cycle shifting to S and G2/M phases in the C2C12 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | SY-LB-35 | ||||||||||||
| CAS | 2603461-70-5 | ||||||||||||
| Formula | C15H11N3O | ||||||||||||
| Molar Mass | 249.27 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Najafi S, et al. Discovery of a novel class of benzimidazoles as highly effective agonists of bone morphogenetic protein (BMP) receptor signaling. Sci Rep. 2022 Jul 15;12(1):12146. |